Innovation-driven development is the main theme of today’s world . China is entering a new era of innovation-driven development, but despite being the world’s second largest pharmaceutical market, China is still far from realizing innovation-driven development. According to the statistical data of IMS Consulting, Chinese generic drugs have a share of above 95% . China’s innovative drug research and development has just started. A national strategy calls for us to accelerate the use of the maxim “first following, then synchronizing, then leading”. The development of innovative pharmaceutical enterprises in China still has a long way to go.

By adhering to its core mission of “Our Life Science Cares Your Health ”, the Konruns Institute of Pharmaceutical Research (the Company) pursues new drug research, in particular new special drugs. Currently, the Company owns Suling, a national first-in-class new drug that has been launched onto the market, and is developing other national first-in-class new drugs, including CX1003, CX1026, and KC1036 and other product combinations.  The Company has applied for 69 patents of invention and obtained 47 authorizations, including 28 authorizations on international PCT patents. The Company has undertaken and completed the National 863 Program, China Torch Program, National Major New Drug Research Project (11th, 12th, and 13th Five-year Plans), and the National High-tech Industry Demonstration Project. The Company has also been awarded multiple top-level honors, including the National Intellectual Property Demonstration Enterprise and China Patent Excellence Award. Hence, the Institute has accumulated solid core competitiveness in terms of innovative drug research and development.

I. A complete R&D system facilitates the research and development  of innovative drugs

Over sixteen years of innovative drug research and development, the research team has accumulated rich experience and capacity in innovative drug research and development and has established a complete R&D system, from topic selection and investigation, to project screening, non-clinical research, clinical research, intellectual property protection, industrial transfer, and registration and declaration, and clinical re-study after product launch.

A group of like-minded innovative drug research and development teams with a new global vision has gathered together in the Company. The Company has perfected various departments engaged in innovative drug research and development. A postdoctoral program has been established to focus on original innovative drugs and technologies. All departments of the Institute  are set up to complement each other. In particular, people returning from overseas and other leading talents that have joined the Company in recent years, have brought new concepts and experience into Konruns, which will further the aim of developing innovative new drugs with clinical application in the near future.

II. Scientific management, efficient research, value creation

With more than a decade of innovative drug research and development management, the Company continuously strives to optimize and perfect the drug research and development process, quality systems, and management systems. As a consequence, the research and development management has tended to be more scientific and complete ; and the progress and quality of the development of innovative drugs has been greatly improved. A complete research system, an excellent research and development team, as well as scientific research and development management, has enabled the efficient new drug research and development of the Company and its remarkable achievements.

In terms of market competition, the Company regards innovation as a consistent driving force to build its core competitiveness. In recent years, the Company has continued to increase investments in research and development, thus vigorously supporting the research and development, as well as the innovative development of the Company. Also, the Company has systematically arranged the development of anti-tumor and hemostatic drugs that fail to satisfy clinical needs, and has formed an organic combination in each field, thus forming a rich and reasonable product R&D pipeline.  Several new multi-target drugs with independent intellectual property are being developed.

III. Remaining true to original aspiration, bearing mission in mind, further creating brilliance

Innovative research and development is the fundamental strategy and positioning that Konruns insists on and is a strong driving force for pushing the continuous development of the Company. Since its establishment, the Company has continuously invested in an advanced R&D platform and system at a high level. Committed to building a world-class, high-tech pharmaceutical R&D base, the Institute has shouldered the arduous duty of the new drug development and strategic planning of the Company.  

By adhering to the core mission of “Our Life Science Cares Your Health”, the Company insists on a R&D concept guided by clinical needs and based on scientific innovation, is engaged in the development of chemical and biological drugs, and is focused on research in anti-tumor and hemostatic drugs. Based on the above concepts, the Company has also systematically formulated and planned an innovative drug research and development strategy that features a steady transition from “domestic new drugs” to “global new drugs”.